Moderna's Flu Vaccine Shows Positive Results in Trial, Clearing Path for Combo Shot

Moderna announced that its experimental mRNA-based flu vaccine showed a stronger immune response compared to the current available shot in a late-stage trial. This paves the way for the product and the company's combination flu and Covid jab.

In May, Moderna withdrew its application for the combination shot targeting Covid-19 and influenza, planning to resubmit it with efficacy data from the phase three trial on its standalone flu vaccine. The company intends to resubmit the application for the combination vaccine and seek approval for its standalone flu shot later this year.

If approved, Moderna can advance the combination shot, simplifying vaccination and reducing healthcare system workloads and costs. The company anticipates approvals for both shots next year.

The phase three trial included over 40,000 adults aged 50 and above, showing Moderna's shot was 26.6% more effective than the standard competitor vaccine. The vaccine demonstrated strong efficacy across major influenza strains and different age groups.

Moderna CEO Stephane Bancel highlighted the significance of the efficacy results, emphasizing the need for more effective vaccines to reduce the burden of influenza in older adults.

Data from the CDC revealed a high number of flu-related hospitalizations and outpatient visits during the 2024-2025 season, underscoring the importance of improved vaccines.

Moderna is engaging closely with the FDA to navigate the regulatory environment and meet requirements for its flu vaccines.

According to the source: CNBC.